The new research topics have been approved by the IMI Board, after extensive consultation between various stakeholders; including the IMI scientific committee, Member states representatives, the European commission and pharmaceutical companies that are members of EFPIA.
IMI juhatus kiitis uued uurimisteemad heaks pärast ulatuslikke arutelusid eri sidusrühmade vahel, kuhu kuuluvad muu hulgas IMI teaduskomitee, liikmesriikide esindajad, Euroopa Komisjon ja EFPIA liikmetest farmaatsiaettevõtted.